These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 30678050)

  • 61. 4-1BB-based isolation and expansion of CD8+ T cells specific for self-tumor and non-self-tumor antigens for adoptive T-cell therapy.
    Choi BK; Lee SC; Lee MJ; Kim YH; Kim YW; Ryu KW; Lee JH; Shin SM; Lee SH; Suzuki S; Oh HS; Kim CH; Lee DG; Hwang SH; Yu EM; Lee IO; Kwon BS
    J Immunother; 2014 May; 37(4):225-36. PubMed ID: 24714356
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effects of concomitant temozolomide and radiation therapies on WT1-specific T-cells in malignant glioma.
    Chiba Y; Hashimoto N; Tsuboi A; Oka Y; Murao A; Kinoshita M; Kagawa N; Oji Y; Hosen N; Nishida S; Sugiyama H; Yoshimine T
    Jpn J Clin Oncol; 2010 May; 40(5):395-403. PubMed ID: 20364021
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
    Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
    J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Neoantigen-Specific Adoptive Cell Therapies for Cancer: Making T-Cell Products More Personal.
    Bianchi V; Harari A; Coukos G
    Front Immunol; 2020; 11():1215. PubMed ID: 32695101
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A new peptide vaccine OCV-501: in vitro pharmacology and phase 1 study in patients with acute myeloid leukemia.
    Kobayashi Y; Sakura T; Miyawaki S; Toga K; Sogo S; Heike Y
    Cancer Immunol Immunother; 2017 Jul; 66(7):851-863. PubMed ID: 28321480
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Soluble and membrane-bound interleukin (IL)-15 Rα/IL-15 complexes mediate proliferation of high-avidity central memory CD8
    Hasan AN; Selvakumar A; Shabrova E; Liu XR; Afridi F; Heller G; Riviere I; Sadelain M; Dupont B; O'Reilly RJ
    Clin Exp Immunol; 2016 Nov; 186(2):249-265. PubMed ID: 27227483
    [TBL] [Abstract][Full Text] [Related]  

  • 67. "Cancer antigen WT1 protein-derived peptide"-based treatment of cancer -toward the further development.
    Oka Y; Tsuboi A; Fujiki F; Shirakata T; Nishida S; Hosen N; Nakajima H; Li Z; Kawase I; Oji Y; Sugiyama H
    Curr Med Chem; 2008; 15(29):3052-61. PubMed ID: 19075652
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Elimination of leukemic CD34+ progenitor cells by using cytotoxic T lymphocytes specifically targeting WT1-derived peptide: an experimental study in vitro].
    Gu WY; Chen ZX; Qiu GQ; Hu SY; Jia L; Wu W; He J; Cen JN; He B
    Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3401-6. PubMed ID: 19159569
    [TBL] [Abstract][Full Text] [Related]  

  • 69. WT1 vaccination in acute myeloid leukemia: new methods of implementing adoptive immunotherapy.
    Rein LA; Chao NJ
    Expert Opin Investig Drugs; 2014 Mar; 23(3):417-26. PubMed ID: 24521058
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Detection and preliminary characterization of CD8+T lymphocytes specific for Wilms' tumor antigen in patients with non-Hodgkin lymphoma.
    Israyelyan A; La Rosa C; Tsai W; Kaltcheva T; Srivastava T; Aquino L; Li J; Kim Y; Palmer J; Streja L; Senitzer D; Zaia JA; Rosenwald A; Forman SJ; Nakamura R; Diamond DJ
    Leuk Lymphoma; 2013 Nov; 54(11):2490-9. PubMed ID: 23480492
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Immunotherapy for leukemia targeting the Wilms' tumor gene.
    Yasukawa M
    Leuk Lymphoma; 2001 Jul; 42(3):267-73. PubMed ID: 11699391
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials.
    Van Driessche A; Berneman ZN; Van Tendeloo VF
    Oncologist; 2012; 17(2):250-9. PubMed ID: 22291091
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells.
    Xue SA; Gao L; Hart D; Gillmore R; Qasim W; Thrasher A; Apperley J; Engels B; Uckert W; Morris E; Stauss H
    Blood; 2005 Nov; 106(9):3062-7. PubMed ID: 16020516
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Identification of heme oxygenase-1-specific regulatory CD8+ T cells in cancer patients.
    Andersen MH; Sørensen RB; Brimnes MK; Svane IM; Becker JC; thor Straten P
    J Clin Invest; 2009 Aug; 119(8):2245-56. PubMed ID: 19662679
    [TBL] [Abstract][Full Text] [Related]  

  • 75. WT1 peptide-based immunotherapy for patients with lung cancer: report of two cases.
    Tsuboi A; Oka Y; Osaki T; Kumagai T; Tachibana I; Hayashi S; Murakami M; Nakajima H; Elisseeva OA; Fei W; Masuda T; Yasukawa M; Oji Y; Kawakami M; Hosen N; Ikegame K; Yoshihara S; Udaka K; Nakatsuka S; Aozasa K; Kawase I; Sugiyama H
    Microbiol Immunol; 2004; 48(3):175-84. PubMed ID: 15031530
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies.
    Elisseeva OA; Oka Y; Tsuboi A; Ogata K; Wu F; Kim EH; Soma T; Tamaki H; Kawakami M; Oji Y; Hosen N; Kubota T; Nakagawa M; Yamagami T; Hiraoka A; Tsukaguchi M; Udaka K; Ogawa H; Kishimoto T; Nomura T; Sugiyama H
    Blood; 2002 May; 99(9):3272-9. PubMed ID: 11964293
    [TBL] [Abstract][Full Text] [Related]  

  • 77. CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function.
    Ruggiero E; Carnevale E; Prodeus A; Magnani ZI; Camisa B; Merelli I; Politano C; Stasi L; Potenza A; Cianciotti BC; Manfredi F; Di Bono M; Vago L; Tassara M; Mastaglio S; Ponzoni M; Sanvito F; Liu D; Balwani I; Galli R; Genua M; Ostuni R; Doglio M; O'Connell D; Dutta I; Yazinski SA; McKee M; Arredouani MS; Schultes B; Ciceri F; Bonini C
    Sci Transl Med; 2022 Feb; 14(631):eabg8027. PubMed ID: 35138911
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Neoantigens in Hematologic Malignancies.
    Biernacki MA; Bleakley M
    Front Immunol; 2020; 11():121. PubMed ID: 32117272
    [TBL] [Abstract][Full Text] [Related]  

  • 79. IL15 can reverse the unresponsiveness of Wilms' tumor antigen-specific CTL in patients with prostate cancer.
    King JW; Thomas S; Corsi F; Gao L; Dina R; Gillmore R; Pigott K; Kaisary A; Stauss HJ; Waxman J
    Clin Cancer Res; 2009 Feb; 15(4):1145-54. PubMed ID: 19228720
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen.
    Rafiq S; Purdon TJ; Daniyan AF; Koneru M; Dao T; Liu C; Scheinberg DA; Brentjens RJ
    Leukemia; 2017 Aug; 31(8):1788-1797. PubMed ID: 27924074
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.